The drug is prescribed for neuralgia, myalgia, arthralgia.
active substances: menthol, novocaine (procaine hydrochloride), anesthesia (benzocaine);
100 ml of solution contain menthol – 2.5 g, novocaine (procaine hydrochloride) – 1 g, anesthesia (benzocaine) – 1 g;
excipient: ethanol 70%.
Solution for external use, alcohol.
This pharmaceutical drug Menovazin belongs to the group of antipruritic drugs, which consist of a combination of various components.
The action of the drug is due to the reciprocal action of its constituent substances.
Menthol, which is part of it, for example, has a selective effect, due to which, when applied topically, the drug has a slight cooling effect, since it affects the cold receptors.
Due to the reflex reaction of the skin, the vascular tone changes, and it affects both superficial and deeper blood vessels. Also has a mild anesthetic effect.
Thanks to novocaine (procaine), surface anesthesia appears.
The presence of several components with local anesthetic action enhances the analgesic effect. The drug has the ability to have a reversible effect of disturbance of excitability on nerve receptors, as well as on the conductors of nerve impulses (with direct contact with the drug).
It also has a distracting and local irritating effect, inhibiting the state of excitation in the membranes of nerve fibers, increasing the level of their depolarization.
In general, under the influence of this drug, the degree of excitation in the elements of the nervous system decreases, and the effect of local anesthesia occurs.
This drug Menovazin is used for the topical treatment of certain conditions that are accompanied by pain or itching. In particular, when treating:
- neuralgia of various genesis;
- myalgia (muscle pain);
- arthralgia (joint pain);
- dermatoses, accompanied by itching.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
It is not applied to the surface of the skin where the integrity of the skin is compromised.
It should be borne in mind that the components contained in the preparation are capable of weakening the antibacterial effect of sulfanilamide drugs.
Also, you should not use the drug in the treatment of children under 12 years of age.
Application during pregnancy and lactation
This drug should be used with caution in the treatment of pregnant women, always based on careful weighing of the risk / benefit ratio, since this drug has not been tested in pregnant women.
If it is necessary to take the drug during breastfeeding, then lactation should be suspended during treatment.
Method of administration and dosage
This Menovazin preparation is intended for topical use, applied to the skin surface, except in places where the integrity of the skin is compromised.
To achieve an analgesic effect, apply 2-3 times a day, rubbing into the skin with light rubbing in a circular motion.
Place of application – the skin over the affected area (joint, muscle).
The duration of the course of treatment depends on the type of disease, its form and type, as well as on the type of therapy chosen by the attending physician as a concomitant treatment.
With excessively prolonged use, symptoms of intoxication may appear in the form of:
- general weakness;
- lowering blood pressure;
- various allergic reactions, including local ones – itching, skin redness, allergic dermatitis.
When such symptoms appear, the application of the drug should be canceled, and its remnants should be washed off the skin surface with warm water and reported to the attending physician.
In general, symptomatic treatment is recommended.
The drug rarely causes side effects and is well tolerated.
The following side effects are possible, such as:
- itching, rash, allergic urticaria;
- hyperemia (redness) of the skin;
- skin irritation;
- edema, contact dermatitis.
Storage conditions and periods
The shelf life is up to 2 years.
Storage temperature should not exceed 25 ° C.